Zydus Lifesciences has received final approval from the USFDA for Verapamil Hydrochloride Extended-Release Tablets USP in strengths of 120 mg, 180 mg, and 240 mg. These tablets are used to treat high blood pressure, reducing the risk of heart problems. The product will be manufactured at Zydus Lifesciences Ltd. in Baddi, Himachal Pradesh.
USFDA Approval for Verapamil Tablets
Zydus Lifesciences has secured final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, available in dosages of 120 mg, 180 mg, and 240 mg. This approval was announced on November 25, 2025.
Therapeutic Use
The Verapamil Hydrochloride Extended-Release Tablets are designed to lower high blood pressure, which is crucial in reducing the likelihood of severe cardiovascular events, including strokes and heart attacks.
Manufacturing Location
The production of these tablets will be based at Zydus Lifesciences Ltd.’s facility located in Baddi, Himachal Pradesh.
Market Data
As of September 2025, the annual sales for Verapamil Hydrochloride Extended-Release Tablets in the United States amounted to USD 24.5 million, according to IQVIA data.
ANDA Filings and Approvals
To date, Zydus Lifesciences has received 428 approvals and has filed 487 ANDAs since the start of its filing process in FY 2003-04.
Source: BSE